Understand · Treat · Recover

Primary Surgery Versus Neoadjuvant Chemotherapy

Choosing the order of treatment is about the safest route to effective disease control.

This guide is educational and does not replace individual medical assessment. Do not start, stop or change treatment without the treating team. Cancer Aware supports patients and families worldwide. Drug approvals, availability, affordability and care pathways vary by country.

Chapter 10 of 20

Specialist assessmentPathology · extent · fitness · goals
Surgery firstComplete removal likely and acceptable surgical riskChemotherapy when indicated
Chemotherapy firstComplete removal unlikely or surgical risk too highReassess for interval surgery, then further treatment
Response reviewMaintenance or observation · symptom support · follow-up
A simplified advanced epithelial cancer pathway. Rare subtypes and individual circumstances may require a different plan.

When surgery first is preferred

Primary cytoreductive surgery is generally favoured for a fit patient when the specialist team believes complete removal of visible advanced disease is likely with acceptable morbidity. Scans, clinical assessment and sometimes diagnostic laparoscopy help estimate that likelihood. A large tumour alone does not settle the decision.

When chemotherapy first is preferred

Neoadjuvant chemotherapy is appropriate when complete cytoreduction is unlikely or operative risk is high. It can shrink disease and allow time to improve symptoms or fitness. Tissue confirmation should generally precede treatment. Interval surgery is considered after response or stable disease, commonly after three cycles and generally by four cycles when appropriate, followed by further chemotherapy.

What if the cancer does not shrink?

Progression during initial chemotherapy requires reassessment of the pathology, treatment options and goals. Interval surgery is not an automatic next step in this situation. Symptom management, alternative systemic options or a clinical trial may be more appropriate.

Questions for the multidisciplinary team

  • What is the estimated chance of no visible residual disease with surgery now?
  • What is my surgical complication risk?
  • How and when will response be assessed if chemotherapy comes first?
  • Which findings would change the plan?

Key takeaway

The best sequence is the one suited to resectability, fitness and the tumour’s behaviour.

Common questions

Is chemotherapy first a weaker treatment?

No. It is an established approach for appropriately selected advanced disease.

Can age alone decide the sequence?

No. Functional fitness, comorbidities and disease distribution matter.

Is surgery guaranteed after chemotherapy?

No. The decision depends on response, fitness and whether useful resection is feasible.

Does every patient need laparoscopy?

No. It is used when it helps resolve uncertainty about operability.

Can a second specialist opinion help?

Yes, especially when operability or the balance of surgical risk is uncertain.

Sources and further reading